Greater occipital nerve (GON)

The greater occipital nerve (GON) is a prominent peripheral sensory nerve that originates primarily from the medial branch of the dorsal ramus of the second cervical spinal nerve (C2) [1]. It provides the majority of the cutaneous sensory innervation to the posterior scalp, extending from the occipital region up to the vertex [1]. While not a molecular target in the traditional sense, the GON is a critical anatomical target for therapeutic procedures, such as nerve blocks and radiofrequency ablation, used to manage chronic headache and craniofacial pain syndromes [2]. Pathological compression or irritation of the nerve can lead to occipital neuralgia, characterized by paroxysmal lancinating pain [4]. Pharmacological modulation of the nerve involves the application of local anesthetics, which bind to sodium channels on the axonal membrane to inhibit pain signaling, and corticosteroids, which exert anti-inflammatory effects to reduce nerve hyperexcitability [2][3]. Understanding its course and clinical role is essential for biotech analysts evaluating interventional pain management therapies and neuromodulation devices [5]. Sources: [1] StatPearls: "Anatomy, Head and Neck, Greater Occipital Nerve" [2] NIH/PMC: "Greater Occipital Nerve Block: A Review of Techniques and Clinical Applications" [3] PubMed: "Botulinum Toxin Type A for the Treatment of Occipital Neuralgia" [4] American Association of Neurological Surgeons (AANS): "Occipital Neuralgia" [5] Journal of Pain Research: "Neuromodulation of the Greater Occipital Nerve for Chronic Pain Management"

Other names

Nervus occipitalis majorMedial branch of the dorsal ramus of C2

Interventions targeting the greater occipital nerve typically involve local anesthetics that inhibit voltage-gated sodium channels to block action potential propagation, or corticosteroids that reduce perineural inflammation and stabilize neuronal membranes [1][2]. Botulinum toxin may also be used to inhibit the release of nociceptive neurotransmitters from nerve endings [3].